These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 29658109)

  • 21. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EP4 receptor promotes invadopodia and invasion in human breast cancer.
    Tönisen F; Perrin L; Bayarmagnai B; van den Dries K; Cambi A; Gligorijevic B
    Eur J Cell Biol; 2017 Mar; 96(2):218-226. PubMed ID: 28094049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
    Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.
    Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P
    Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of PGE
    Huang H; Aladelokun O; Ideta T; Giardina C; Ellis LM; Rosenberg DW
    Sci Rep; 2019 Mar; 9(1):4954. PubMed ID: 30894570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44
    Hui D; Chen J; Jiang Y; Pan Y; Zhang Z; Dong M; Shao C
    Exp Cell Res; 2020 May; 390(2):111968. PubMed ID: 32197932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis.
    Valès S; Bacola G; Biraud M; Touvron M; Bessard A; Geraldo F; Dougherty KA; Lashani S; Bossard C; Flamant M; Duchalais E; Marionneau-Lambot S; Oullier T; Oliver L; Neunlist M; Vallette FM; Van Landeghem L
    EBioMedicine; 2019 Nov; 49():172-188. PubMed ID: 31662289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
    Zhang ZZ; Yu WX; Zheng M; Liao XH; Wang JC; Yang DY; Lu WX; Wang L; Zhang S; Liu HK; Zhou XZ; Lu KP
    Mol Cancer Ther; 2020 Mar; 19(3):906-919. PubMed ID: 31879364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.
    Parida S; Parekh A; Dey G; Ghosh SC; Mandal M
    Cancer Biol Ther; 2015; 16(6):922-32. PubMed ID: 25894216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
    Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
    Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non-small-cell lung cancer.
    Huang TH; Wu ATH; Cheng TS; Lin KT; Lai CJ; Hsieh HW; Chang PM; Wu CW; Huang CF; Chen KY
    J Cell Mol Med; 2019 Dec; 23(12):8184-8195. PubMed ID: 31638335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2 induces oncogenic micro RNA miR655 in human breast cancer.
    Majumder M; Dunn L; Liu L; Hasan A; Vincent K; Brackstone M; Hess D; Lala PK
    Sci Rep; 2018 Jan; 8(1):327. PubMed ID: 29321644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer.
    Cao HZ; Liu XF; Yang WT; Chen Q; Zheng PS
    Cell Death Dis; 2017 Sep; 8(9):e3039. PubMed ID: 28880275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer.
    Roscigno G; Puoti I; Giordano I; Donnarumma E; Russo V; Affinito A; Adamo A; Quintavalle C; Todaro M; Vivanco MD; Condorelli G
    Oncotarget; 2017 Mar; 8(12):19507-19521. PubMed ID: 28061479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.